$-0.14 EPS Expected for Check-Cap Ltd. (CHEK)

March 14, 2018 - By Winifred Garcia

 $ 0.14 EPS Expected for Check Cap Ltd. (CHEK)

Analysts expect Check-Cap Ltd. (NASDAQ:CHEK) to report $-0.14 EPS on March, 15.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, Check-Cap Ltd.’s analysts see 7.69 % EPS growth. The stock increased 4.41% or $0.03 during the last trading session, reaching $0.71. About 284,389 shares traded or 8.27% up from the average. Check-Cap Ltd. (NASDAQ:CHEK) has declined 2.26% since March 14, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.

Check-Cap Ltd. (NASDAQ:CHEK) Ratings Coverage

Among 4 analysts covering Check-Cap (NASDAQ:CHEK), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Check-Cap had 12 analyst reports since July 22, 2015 according to SRatingsIntel. As per Tuesday, March 13, the company rating was initiated by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Friday, August 11. The rating was maintained by Maxim Group with “Buy” on Tuesday, January 19. The firm earned “Buy” rating on Tuesday, November 28 by H.C. Wainwright. The stock of Check-Cap Ltd. (NASDAQ:CHEK) earned “Buy” rating by Chardan Capital Markets on Wednesday, July 22. Maxim Group initiated the stock with “Buy” rating in Thursday, October 8 report. The firm has “Buy” rating given on Wednesday, March 16 by Chardan Capital Markets. H.C. Wainwright maintained the shares of CHEK in report on Thursday, January 11 with “Buy” rating. As per Thursday, September 28, the company rating was maintained by H.C. Wainwright. The company was initiated on Thursday, January 19 by Rodman & Renshaw.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. The company has market cap of $13.68 million. The Company’s C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. It currently has negative earnings.

More notable recent Check-Cap Ltd. (NASDAQ:CHEK) news were published by: Prnewswire.com which released: “Check-Cap Ltd. Announces Closing of $2.69 Million Financing” on June 02, 2017, also Prnewswire.com with their article: “Check-Cap Initiates EU Post Approval Study Using Advanced C-ScanĀ®” published on March 12, 2018, Prnewswire.com published: “Check-Cap Ltd. Announces $2.69 Million Financing” on May 30, 2017. More interesting news about Check-Cap Ltd. (NASDAQ:CHEK) were released by: Prnewswire.com and their article: “Check-Cap Announces Acceptance of Late Breaking Clinical Performance Abstract …” published on October 24, 2017 as well as Prnewswire.com‘s news article titled: “Check-Cap Ltd. Announces Closing of $2.5 Million Registered Direct Offering” with publication date: November 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.